# Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

> **NCT01661257** · PHASE3 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT01661257
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661257, "Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01661257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*